Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 13/20 | 0.73 |
| ▸ | GRIK2 | Q13002 | 12/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.56 |
| ▸ | PAM | P19021 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504608 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL1865552 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL3579939 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL3579937 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL8087387 | 1.00 | GRIK1 (0.73) | GRIK1GRIK2HTR2AGRIK3PAM | |
| SCHEMBL594002 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL594001 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL594000 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL593999 | 0.85 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 | |
| SCHEMBL2354701 | 0.84 | GRIK1 (0.55) | GRIK1GRIK2GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-01-27 | — | — | US | claimed |
| US-20240279280-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-22 | — | — | US | claimed |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-05-07 | — | — | US | claimed |
| US-20210155659-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2021-05-27 | — | — | US | claimed |
| EP-3773663-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | Cambridge Enterprise Limited (GB) | 2021-02-17 | — | — | EP | claimed |
| CN-112165953-A | Compounds useful as apelin receptor antagonists | 剑桥企业有限公司 | 2021-01-01 | — | — | CN | claimed |
| WO-2019193355-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | DAVENPORT ANTHONY PETER (GB) | 2019-10-10 | — | — | WO | claimed |
| EP-1084137-B1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-02-18 | — | — | EP | claimed |
| US-6867284-B1 | Peptide inhibitors of hepatitis C virus NS3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-03-15 | — | — | US | claimed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-01-27 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| CN-112165953-B | Compounds useful as apelin receptor antagonists | 剑桥企业有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2003006620-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020150961-A1 | Activity-dependent cysteine protease profiling reagent | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY MANAGEMENT | 2002-10-17 | — | — | US | disclosed |
| WO-2002064091-A2 | MELANOCORTIN METALLOPEPTIDES FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1208377-A1 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | Palatin Technologies, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2002038540-A2 | ACTIVITY-DEPENDENT CYSTEINE PROTEASE PROFILING REAGENT | THE REGENTS OF THE UNIVERISTY OF CALIFORNIA (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2001013112-A1 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | PALATIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534498-B2 | Compounds for use as apelin receptor antagonists | APLNR, NPBWR1, AP3B1 | GRIK1 940/4885GRIK2 1547/4885HTR2A 169/4885 |
| US-11976137-B2 | Compounds for use as apelin receptor antagonists | APLNR, GIPR, GRPR | GRIK1 531/4885GRIK2 719/4885HTR2A 752/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | GRIK1 4649/4885GRIK2 4772/4885HTR2A 2430/4885 |
| US-20020150961-A1 | Activity-dependent cysteine protease profiling reagent | DNPEP, CPB1, ENPEP | GRIK1 2469/4885GRIK2 2979/4885HTR2A 4021/4885 |
| US-20210155659-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | APLNR, GIPR, GRPR | GRIK1 531/4885GRIK2 719/4885HTR2A 752/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | GRIK1 4089/4885GRIK2 4198/4885HTR2A 2976/4885 |
| US-20240279280-A1 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | APLNR, GIPR, GRPR | GRIK1 531/4885GRIK2 719/4885HTR2A 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.